Lipid Testing After Myocardial Infarction at the Montreal Heart Institute

Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization. It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute. Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission. Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.

NCT Number	NCT06388668
Lead Sponsor	Montreal Heart Institute Collaborators: Novartis Pharmaceuticals
Conditions	Dyslipidemias, Lipid Testing, Myocardial Infarction
Enrollment	100 participants
Start Date	2024-06-01
Primary Completion	2026-03 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-12-03